Women with PMOS should get subsidised weight loss drugs, advocates say
Advocates in Australia are calling for government-subsidized access to GLP-1 weight loss drugs for women diagnosed with Polyendrocrine Metabolic Ovarian Syndrome (PMOS). Currently, these medications are expensive and often prescribed off-label for the condition.
Why it matters
The push for equitable access to medical treatments for chronic hormonal conditions highlights gaps in public health policy and affordability.
Symptoms of polyendrocrine metabolic ovarian syndrome include weight gain, hair loss and irregular periods. Photograph: James Manning/PA Symptoms of polyendrocrine metabolic ovarian syndrome include weight gain, hair loss and irregular periods. Photograph: James Manning/PA Health Women with PMOS should get subsidised weight loss drugs, advocates say With GLP-1s to treat the condition not specifically approved by the TGA, patients are being prescribed them off-label
Get our breaking news email , free app or daily news podcast
Prefer the Guardian on Google Women living with a chronic hormonal condition should have access to taxpayer-funded weight loss medications, advocates say.
The Polyendrocrine Metabolic Ovarian Syndrome Association of Australia (POSAA) is urging for GLP-1 drugs to be approved on the Pharmaceutical Benefits Scheme for people living with the condition.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in